Sequent Scientific has received shareholders’ approval for the acquisition of minority stake of 40% in Provet through Alivira Animal Health, Ireland, wholly owned subsidiary of the company. The object of acquisition is to consolidate the shareholding in Provet. Consequent to this acquisition, Provet will become a wholly owned subsidiary of the company. The said transaction is expected to be completed on or before October 31, 2020.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
